Cancer Immunotherapy Market Worth US$ 174.33 billion - UnivDatos Industry Analysis- by Size, Share, Growth, Trends, and Forecast 2021-2027
Research report presented by UnivDatos, Emphasis on
Therapy Type (Monoclonal Antibodies, Vaccines, Checkpoint Inhibitors, Cell
Therapies, Immune System Modulators, Adoptive Cell Transfer, Cytokines, and
Others), Application (Lung cancer, Breast cancer, Colorectal cancer, Melanoma,
Prostate cancer, Head and neck cancer, Others), End-User (Cancer
Specialty/Research Centers, Hospitals & Clinics) and Geographical analysis
(key regions and countries).
As per the research report, Global Cancer Immunotherapy Market is expected to reach the market valuation of USD 174.33 billion by 2027
expanding at a reasonable CAGR of 10.25% during the forecast period (2021-2027)
from USD 87.4 billion in 2020.
Traditional
cancer treatments remain the most widely used and accepted therapies in today's
medical anti-cancer strategies. They include surgery, chemotherapy, and
radiation therapy, with cancer immunotherapy emerging as a newer, more widely accepted
approach that was only recently developed and approved. In early 2018, the FDA
or EMA licenced approximately 32 monoclonal antibodies for cancer immunotherapy
for a cancer diagnosis and medical purpose. The demand is expected to rise due
to increasing cancer incidence and a growing geriatric population. In 2020, an
estimated 19.3 million new cancer patients will be diagnosed worldwide (18.1
million minus nonmelanoma skin cancer), with almost 10.0 million cancer deaths
(9.9 million excluding nonmelanoma skin cancer). With an unprecedented 2.3
million new diagnoses (11.7 percent), female breast cancer has replaced lung
cancer as the most often diagnosed cancer, led by lung (11.4 percent),
colorectal (10.0 percent), prostate (7.3 percent), and abdominal (5.6 percent)
cancers.
For complete research, request for
Sample of the report browse through – https://univdatos.com/request_form/form/364
According
to a report performed in 2019 by Alyson Haslam and Vinay Prasad titled
"Estimation of the Proportion of US Patients with Cancer Who Are Eligible
for and Respond to Checkpoint Inhibitor Immunotherapy Drugs," the average
percentage of eligible cancer patients in the US for checkpoint inhibitor drugs
was 1.54 percent in 2011 and rose to an estimated 26.86 percent by 2015 and
43.6 percent by 2016. Furthermore, the diseases that contributed the most to
the eligibility calculation were NSCLC (21.48 percent), hepatocellular
carcinoma (4.95 percent), and SCLC (3.79 percent). Despite accounting for only
9% of FDA-approved oncology drugs, immunotherapy treatments accounted for 33%
of oncology drug spending in 2016. Immunotherapy pipelines are being built by
all of the major oncology drug makers, resulting in expanded M&A and
investor interest. Several cancer immunotherapies, such as monoclonal
antibodies, have a variety of clinically important modes of action, such as
killing tumour cells specifically and also facilitating the activation of long-lasting
anti-tumor immune responses. Several cancer patients around the world endured
long-term city lockdowns and delays in receiving immunotherapies after the
COVID-19 outbreak. In China, for example, treatment found that a three- to
four-month interval had only a minor, if any, effect on immunotherapy
effectiveness in patients with well-controlled disease.
For a detailed analysis of the applications in the Cancer Immunotherapy Market browse
through – https://univdatos.com/report/cancer-immunotherapy-market-current-analysis-and-forecast-2021-2027
Insights Presented in the Report
“Amongst therapy, monoclonal antibodies segment holds the major share”
The
market is divided into monoclonal antibodies, vaccinations, checkpoint
inhibitors, cell therapies, immune system modulators, adoptive cell transfer,
cytokines, and others based on the method of treatment. Due to the diverse range of
clinically important mechanisms of action, the monoclonal antibodies segment
dominated the market with a share of 37.3 percent in 2020 and is projected to
continue its dominance throughout the forecast period.
“Amongst application, breast cancer is anticipated to grow at the
highest CAGR during the analyzed period”
The industry is
further divided into lung cancer, breast cancer, colorectal cancer, melanoma,
prostate cancer, head among neck cancer, and other cancer applications
depending on application. Lung cancer had a market sales share of 25.5 percent
in 2020 and is projected to stay competitive over the forecast period. The
breast segment, on the other hand, is expected to rise at the fastest CAGR
during the forecast period, reaching a market valuation of USD 36.10 million by
the end of the year. Breast cancer is responsible for one out of every four
cancer cases and one out of every six cancer deaths.
Amongst end-user, cancer specialty/research centers segment holds the
major share”
The
market is divided into two types of end-users: Cancer Specialty/Research
Centers and hospitals and clinics. With sales of USD 55.43 billion in 2020,
cancer specialty/research centres led the industry, and this domination is
expected to continue over the forecast era. Furthermore, during the forecast
era, the segment is projected to rise at the fastest CAGR.
“North America signifies one of the largest markets of Cancer
Immunotherapy Market”
A
systematic research was performed for various regions around the globe,
including North America (United States, Canada, and the Rest of North America),
Europe (Germany, France, Italy, Spain, United Kingdom, and the Rest of Europe),
Asia-Pacific (China, Japan, India, and the Rest of APAC), and the Rest of the
World to get a greater understanding of the global dynamics of the Cancer
Immunotherapy market. North America dominated the market in 2020, bringing in USD 37.56
billion in sales. Nearly 1.9 million additional cancer patients are projected
to be diagnosed in the United States in 2021. In 2021, an estimated 608,570
Americans will die from cancer, equating to around 1,670 deaths every day.
Cancer is the second leading cause of death in the United States, after only
heart disease.
Customization Options:
The Cancer Immunotherapy Market can further
be customized as per the requirement or any other market segment. Besides this,
UMI understands that you may have your own business needs, hence feel free to
connect with us to get a report that completely suits your requirements.
Table of Contents
1 Market
Introduction
2 Research
Methodology or Assumption
3 Market
Synopsis
4 Executive
Summary
5 Top
Start-Ups Under Cancer Immunotherapy Sector
6 Cancer
Immunotherapy Amid COVID-19
7 Global
Cancer Immunotherapy Market Revenue (USD Bn), 2019-2027f
8 Market
Insights by Therapy
9 Market
Insights by Application
10 Market
Insights by End-User
11 Market
Insights by Region
12 Cancer
Immunotherapy Market Dynamics
13 Cancer
Immunotherapy Market Opportunities
14 Cancer Immunotherapy Market
Trends
15 Legal &
Regulatory Framework
16 Demand and
Supply Side Analysis
17 Value Chain
Analysis
18 Competitive
Scenario
19 Company
Profiled - AbbVie, Amgen, AstraZeneca, bluebird bio, Bristol-Myers Squibb, F.
Hoffmann-La Roche, Janssen Biotech, Merck, Novartis, and Pfizer
20 Disclaimer
Labels: Cancer Immunotherapy Market, Cancer Immunotherapy Market growth, Cancer Immunotherapy Market share, Cancer Immunotherapy Market size
0 Comments:
Post a Comment
Subscribe to Post Comments [Atom]
<< Home